Summary & Overview

HCPCS Level II J8522: Capecitabine, Oral, 50 mg

HCPCS Level II code J8522 identifies capecitabine 50 mg, an oral antineoplastic agent commonly prescribed for several solid tumor indications. Nationally, accurate coding for oral chemotherapy is important for claims processing, patient cost-sharing, and program tracking of oral cancer therapies. Oral agents like capecitabine shift parts of chemotherapy delivery from infusion suites to outpatient pharmacies and clinic-managed oral chemotherapy programs, affecting billing workflows and benefit determinations.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for capecitabine, typical sites of service, and the implications of using an HCPCS Level II code for an oral oncology medication. The publication summarizes common modifiers and payer coverage patterns where available, national billing benchmarks and reimbursement considerations, and policy updates relevant to oral antineoplastic billing and coverage. It also highlights operational considerations for documenting dispensed units and coordinating pharmacy benefits versus medical benefits.

Data not available in the input for specific associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer-specific reimbursement rates. The report is intended for national audiences involved in oncology billing, pharmacy services, and payer policy.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ8522HCPCS Level IIcapecitabineoral chemotherapyoncologypharmacy billingoutpatientantineoplastic

Billing Code Overview

HCPCS Level II code J8522 represents Capecitabine, oral, 50 mg. This code denotes a prescription oral chemotherapeutic agent provided in 50 mg unit dosing.

Service type: Oral antineoplastic (chemotherapy) agent

Typical site of service: Outpatient pharmacy or clinic-managed oral chemotherapy program

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 64-year-old patient with stage III colorectal adenocarcinoma is prescribed oral chemotherapy with capecitabine, J8522 (capecitabine, oral, 50 mg) as part of an adjuvant regimen following surgical resection. The patient receives medication dispensing and counseling at an outpatient oncology infusion and pharmacy clinic or specialty pharmacy. The clinical workflow includes prescription entry and verification by an oncologist or advanced practice provider, pharmacist dosing review and counseling, medication dispensing with appropriate counts and labeling, documentation of start date and intended cycles in the electronic health record, baseline and periodic labs (complete blood count, liver function tests, renal function), and scheduled follow-up visits to assess tolerance, toxicity, and response. Dose modifications or treatment holds are documented when toxicity occurs, using modifiers if required for billing. Typical sites of service are outpatient oncology clinics, specialty infusion pharmacies, hospital outpatient pharmacies, and home oral chemotherapy administration with clinical oversight.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no other modifier applies to the service for the medication.
`22`	Increased procedural services	Use when an unusually high level of clinical work or complexity is required for medication management or counseling beyond typical dispensing.
`23`	Unusual anesthesia	Not typically applicable to oral chemotherapy; may be listed if anesthesia-related services occurred (rare).
`52`	Reduced services	Use when the medication supply or service is partially reduced from what is usually provided.
`53`	Discontinued procedure	Use when planned medication administration or dispensing was discontinued prior to completion.
`54`	Surgical care only	Not typically applicable for oral chemotherapy billing for the drug itself.
`55`	Postoperative management only	Not typically applicable for the drug billing.
`56`	Preoperative management only	Not typically applicable for the drug billing.
`62`	Two surgeons	Rarely applicable; use when two surgeons are involved in an associated surgical service.
`78`	Unplanned return to the operating room	Not applicable to oral drug billing unless tied to surgical complications requiring reoperation.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery	Not typically applicable for dispensing drugs.
`CO`	Items or services ordered by a worker's compensation plan	Use when the claim is related to worker's compensation billing.
`CQ`	Service furnished under a primary care exception	Use when services are billed under the primary care exception rules where applicable.
`JW`	Drug discarded/not administered to any patient	Use when part or all of a single-use vial or dose is discarded and documentation supports waste billing rules.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Medical Oncology	Oncologists prescribe and oversee capecitabine therapy and dosing.
`207RC0000X`	Hematology-Oncology	Hematology-oncology specialists manage systemic chemotherapy regimens.
`363A00000X`	Ambulatory Clinical Pharmacy	Oncology pharmacists perform verification, counseling, and dispensing.
`364S00000X`	Specialty Pharmacy	Specialty pharmacists handle dispensing, prior authorization, and reimbursement coordination.
`2084P0800X`	Nurse Practitioner	NPs in oncology clinics manage prescriptions, follow-up, and toxicity management.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.9`	Malignant neoplasm of colon, unspecified	Capecitabine is commonly used for colon cancer as adjuvant or metastatic therapy.
`C20`	Malignant neoplasm of rectum	Capecitabine is used in rectal cancer treatment often as part of chemoradiation or systemic therapy.
`C50.9`	Malignant neoplasm of breast, unspecified	Capecitabine is indicated for metastatic breast cancer in certain regimens.
`C21.8`	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Relevant when capecitabine is used for anorectal malignancies.
`C79.1`	Secondary malignant neoplasm of bone and bone marrow	Capecitabine may be used for metastatic disease when disease has spread to bone.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Commonly used for follow-up visits to assess tolerance and manage dose adjustments for oral chemotherapy.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be billed for concurrent supportive injections (e.g., growth factors) administered during clinic visits managing chemotherapy side effects.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anticancer drugs, up to 1 hour	Applicable when parenteral chemotherapy or supportive anticancer drug administration occurs in conjunction with oral capecitabine management.
`36415`	Collection of venous blood by venipuncture	Billed for laboratory monitoring (CBC, chemistries) required before or during capecitabine therapy.
`81002`	Urinalysis, non-automated, without microscopy	May be performed as part of routine monitoring when clinically indicated.
`G0490`	Services provided by a community health worker to assist in management of chronic conditions, per encounter	Occasionally used in care coordination programs for oral chemotherapy adherence support.